WO1989000848A1 - Procede permettant de traiter des tissus osseux et de leur administrer des medicaments - Google Patents

Procede permettant de traiter des tissus osseux et de leur administrer des medicaments Download PDF

Info

Publication number
WO1989000848A1
WO1989000848A1 PCT/US1987/003505 US8703505W WO8900848A1 WO 1989000848 A1 WO1989000848 A1 WO 1989000848A1 US 8703505 W US8703505 W US 8703505W WO 8900848 A1 WO8900848 A1 WO 8900848A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxygenated
perfluorocarbon
drugs
tissue
fluid
Prior art date
Application number
PCT/US1987/003505
Other languages
English (en)
Inventor
Edward S. Neiss
Charles G. Smith
Original Assignee
Chemex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemex Pharmaceuticals, Inc. filed Critical Chemex Pharmaceuticals, Inc.
Publication of WO1989000848A1 publication Critical patent/WO1989000848A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to a method for a treatment of and the administration of drugs to body tissues and surfaces.
  • this invention particularly relates to the treatment of structures such as the skin or mucosa which are in need of enhanced or supplemental oxygen supply.
  • This invention also relates to the treatment of individuals or tissues within individuals which may additionally or alternatively require the administration of drugs.
  • Yet another long sought goal of medical science is ' an effective, non-invasive technique for the percutaneous administration of drugs.
  • Most known methods are not well suited to be used by patents (e.g., intraveneous injection) or result in poor absorption and utilization of the drug (e.g., enceric administration). It is therefore an object of this invention to provide a method of treatment which will supplement or restore the-;; oxygen supply to damaged tissues. It is also an object of this invention to provide a method of treatment which facilitates the effective percutaneous administration of drugs which can be useful in the treatment of disease and especially useful in the treatment of damaged or diseased mucosa or skin.
  • damaged bodily tissue is treated by oxygenating a pharmaceutically acceptable liquid with a therapeutically effective amount of oxygen and then applying the oxygenated liquid to the affected tissue.
  • another therapeutic agent is dissolved or suspended in the liquid in addition to • or in place of oxygen.
  • This therapeutic agent may be selected from an exceptionally wide variety of drugs including antibiotics, anti-inflamatories or mixtures of such agents or drugs.
  • Another highly useful group of therapeutic agents are those which are useful in treating skin diseases such as acne, psoriasis, angina pectoris or skin cancers.
  • perfluorinated hydrocarbons are generally insoluble in water it is highly preferred that an aqueous emulsion of the perfluorinated hydrocarbons to be used.
  • Fluosol-DA Green Cross
  • Oxypherol-ET Alpha Therapeutic Corporation. The composition of Oxypherol-ET is set forth in Table II.
  • the Oxypheral-ET formulation may be modified by increasing the hydroxyethyl starch level to from 5- to 20%.
  • the oxygenation of the perfluorocarbon or perfluorocarbon emulsion used in the process of the present invention can be carried out by exposing the fluid to an atmosphere of at least 75% oxygen, although an atmosphere of at least 95% oxygen is preferred. This is most effectively accomplished by bubbling oxygen at slightly greater than atmqspheric pressure through the perfluorocarbon. Once oxygenated, the perfluorocarbon or perfluorocarbon emulsion may be applied directly to damaged tissue.
  • Perfluorocarbon preparations are known to be able to dissolve at least 40% of oxygen and it is desirable to use fully saturated preparations when treating oxygen starved tissues. However, even oxygen starved tissues benefit substantially from the use of 25% solutions.
  • the oxygenated fluid should be applied to the affected tissue at regular intervals to obtain maximum therapeutic effect. It is expected that it will be necessary to reapply the oxygenated fluid to the affected tissue 2 to 6 times each day.
  • topical or percutaneous administration of drugs can be accomplished with special advantage by the process of the present invention and the absorption of drugs is accomplished with suprising effectiveness.
  • the affected tissue has suffered injury as a result of a trama or where secondary infection is present or seriously possible, it will be advisable to include a therapeutic concentration of an appropriate antibotic in the oxygenated perfluorocarbon fluid.
  • Therapeutic concentrations of some suitable topical antibotics are set forth in Table III.
  • Polymyxin B 0.5-1.5% by wt.
  • an anti-inflamatory agent may be included in the oxygen-containing liquid which is used in the present invention.
  • an anti-inflamatory agent may be included in the oxygen-containing liquid which is used in the present invention.
  • hydrocortisone 0.5 to 1.5% by weight
  • Other therapeutic agents which may be used include nordihydroquaiaretic acid and its derivatives, the usefulness of which is described in co-pending United States Patent Application No. 699,923, filed February 2, 1985.
  • a wide variety of drugs can be administered with exceptional effectiveness through healthy skin by the process of the present invention. This process, therefore, has broad application in the percutaneous administration of drugs without regard to its usefulness as an oxygen supply technique.
  • a bedsore may be treated by applying to it sufficient volume of oxygenated Oxypherol-ET to completely over the sore.
  • the sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
  • nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.
  • Oxypherol-ET oxygenated Oxypherol-ET to completely over the sore.
  • the sore can be seen to begin to heal within 2 weeks and heal completely in about 4 weeks as the above described procedure is repeated every 12 hours.
  • nitroglycern can be dissolved in the above-mentioned perfluorocarbon composition and applied in a patch on the skin of a patient suffering from angina pectoris. This procedure can provide immediate and sustained relief to the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On applique un fluide oxygéné aux tissus corporels abîmés, permettant ainsi aux tissus d'être oxygénés. On peut oxygéner et utiliser dans ce procédé des hydrocarbures perfluorés. Divers agents thérapeutiques peuvent être mélangés au fluide oxygéné et administrés aux tissus abîmés.
PCT/US1987/003505 1986-09-19 1987-08-18 Procede permettant de traiter des tissus osseux et de leur administrer des medicaments WO1989000848A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90983286A 1986-09-19 1986-09-19
US909,832 1986-09-19

Publications (1)

Publication Number Publication Date
WO1989000848A1 true WO1989000848A1 (fr) 1989-02-09

Family

ID=25427897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/003505 WO1989000848A1 (fr) 1986-09-19 1987-08-18 Procede permettant de traiter des tissus osseux et de leur administrer des medicaments

Country Status (4)

Country Link
EP (1) EP0324802A4 (fr)
JP (1) JPH01503146A (fr)
AU (1) AU2807689A (fr)
WO (1) WO1989000848A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0493677A2 (fr) * 1991-01-03 1992-07-08 Chiron Adatomed Pharmazeutische und Medizintechnische Gesellschaft mbH Solution pour le recollage d'une rétine décollée à la choroide
EP0494974A1 (fr) * 1989-10-04 1992-07-22 Alliance Pharmaceutical Corporation Emulsions de fluorocarbone contenant des agents anti-inflammatoires a base d'acides amines ainsi que des systemes de tampons
DE4221256A1 (de) * 1992-06-26 1994-01-05 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
EP0576537A1 (fr) * 1991-03-21 1994-01-05 Escalon Ophthalmics, Inc. Extraction de corps etrangers dans des cavites corporelles a l'aide de liquides d'extraction
WO1994024223A1 (fr) * 1993-04-21 1994-10-27 Gordon Stead Epaississement des liquides fluorures
EP0670159A1 (fr) * 1994-02-22 1995-09-06 Hoechst Aktiengesellschaft Emulsions d'huile contenant de fluorocarbures
US5637318A (en) * 1992-06-26 1997-06-10 Lancaster Group Ag Dermatological agent for assisting the transport of oxygen in the skin
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
US5643601A (en) * 1992-06-26 1997-07-01 Lancaster Group Ag Phospholipid-and fluorocarbon-containing cosmetic
US5733939A (en) * 1993-09-29 1998-03-31 Alliance Pharmaceutical Corp. Fluorocarbons as anti-inflammatory agents
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5847009A (en) * 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
US5929039A (en) * 1993-11-15 1999-07-27 Baker Medical Research Institute Method for treating cardiac dysfunction and pharmaceutical compositions useful therefor
US20120225102A1 (en) * 2008-11-25 2012-09-06 Oxygen Biotherapeutics, Inc. Perfluorocarbon gel formulations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061688A (en) * 1988-08-19 1991-10-29 Illinois Institute Of Technology Hemoglobin multiple emulsion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186423A (en) * 1976-10-01 1980-01-29 Matsushita Electric Industrial Company, Limited Solid electrolyte capacitor using oxide of Ru, Rh, Re, Os or Ir as electrolyte
US4366169A (en) * 1979-06-25 1982-12-28 Sun Tech, Inc. Use of perfluorocarbons as wound treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE881267A (fr) * 1980-01-18 1980-05-16 Stein Karl N Methode pour le traitement de brulures de la peau chez les mammiferes
JPS59139252A (ja) * 1982-11-26 1984-08-10 チルドレンズ・ホスピタル・メデイカル・センタ− 眼の眼外処置用装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186423A (en) * 1976-10-01 1980-01-29 Matsushita Electric Industrial Company, Limited Solid electrolyte capacitor using oxide of Ru, Rh, Re, Os or Ir as electrolyte
US4366169A (en) * 1979-06-25 1982-12-28 Sun Tech, Inc. Use of perfluorocarbons as wound treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0324802A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847009A (en) * 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
US6361792B1 (en) 1987-08-05 2002-03-26 Alliance Pharmaceutical Corp. Lipid dispersions and methods of use
EP0494974A1 (fr) * 1989-10-04 1992-07-22 Alliance Pharmaceutical Corporation Emulsions de fluorocarbone contenant des agents anti-inflammatoires a base d'acides amines ainsi que des systemes de tampons
EP0494974A4 (en) * 1989-10-04 1992-09-02 Alliance Pharmaceutical, Inc. Fluorocarbon emulsions containing amino acid based anti-inflammatory agents and buffer systems
EP0493677A3 (en) * 1991-01-03 1992-12-23 Adatomed Pharmazeutische Und Medizin-Technische Gesellschaft Mbh Solution for the reattachment of a detached retina to the choroid
EP0493677A2 (fr) * 1991-01-03 1992-07-08 Chiron Adatomed Pharmazeutische und Medizintechnische Gesellschaft mbH Solution pour le recollage d'une rétine décollée à la choroide
US5397805A (en) * 1991-01-03 1995-03-14 Adatomed Pharmazeutische Und Medizintechnische Gesellschaft Mbh Treatment liquid for reapplying (unfolding) detached retina to the chorioid of the eye
EP0576537A4 (fr) * 1991-03-21 1995-05-03 Escalon Ophthalmics Inc Extraction de corps etrangers dans des cavites corporelles a l'aide de liquides d'extraction.
EP0576537A1 (fr) * 1991-03-21 1994-01-05 Escalon Ophthalmics, Inc. Extraction de corps etrangers dans des cavites corporelles a l'aide de liquides d'extraction
WO1994000110A1 (fr) * 1992-06-26 1994-01-06 Lancaster Group Ag Composition galenique pour application topique
DE4221256A1 (de) * 1992-06-26 1994-01-05 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5637318A (en) * 1992-06-26 1997-06-10 Lancaster Group Ag Dermatological agent for assisting the transport of oxygen in the skin
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
US5643601A (en) * 1992-06-26 1997-07-01 Lancaster Group Ag Phospholipid-and fluorocarbon-containing cosmetic
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
WO1994024223A1 (fr) * 1993-04-21 1994-10-27 Gordon Stead Epaississement des liquides fluorures
US5733939A (en) * 1993-09-29 1998-03-31 Alliance Pharmaceutical Corp. Fluorocarbons as anti-inflammatory agents
US5929039A (en) * 1993-11-15 1999-07-27 Baker Medical Research Institute Method for treating cardiac dysfunction and pharmaceutical compositions useful therefor
EP0670159A1 (fr) * 1994-02-22 1995-09-06 Hoechst Aktiengesellschaft Emulsions d'huile contenant de fluorocarbures
US20120225102A1 (en) * 2008-11-25 2012-09-06 Oxygen Biotherapeutics, Inc. Perfluorocarbon gel formulations

Also Published As

Publication number Publication date
EP0324802A4 (en) 1991-07-24
AU2807689A (en) 1989-03-01
JPH01503146A (ja) 1989-10-26
EP0324802A1 (fr) 1989-07-26

Similar Documents

Publication Publication Date Title
WO1989000848A1 (fr) Procede permettant de traiter des tissus osseux et de leur administrer des medicaments
CN101287457B (zh) Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
EP0279379B1 (fr) Administration interstitielle d'emulsions de composés perfluorés pour la reoxygénation de cellules cancéreuses hypoxiques
Bell et al. Regional anesthesia with intravenous lidocaine
US4555524A (en) Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods
JPS60100517A (ja) 放射線潰瘍治療剤および方法
JP2002510618A (ja) 皮膚科症状の治療へのポリアミンの使用
CA1302253C (fr) Utilisation de protoporphyrine stanneuse et de mesoporptyrine stanneuse dans le traitement du psoriasis
JP2004521112A (ja) 関節痛治療薬を製造することへの神経毒性物質の使用
WO1985005036A1 (fr) Traitement topique du diabete a l'aide d'insuline et d'un agent ameliorant la penetration applique sur la peau et recouvert d'une pastille
CA2599718A1 (fr) Methodes et preparations pharmaceutiques pour le traitement de degats neurologiques
GARB et al. Mycosis fungoides with bullous lesions: report of a case resistant to roentgen and arsenical therapy; effects of empiric therapy, partly based on laboratory investigations
Glick et al. Phase I clinical trials of WR-2721 with alkylating agent chemotherapy
KR0145678B1 (ko) 트리글리세라이드를 함유하는 포도필로톡신 제제
JP2640597B2 (ja) 創傷治癒促進剤
CN114831939B (zh) 一种醋酸曲安奈德组合物喷雾剂及其制备方法
CN1177587C (zh) 利鲁唑和α-生育酚联合制剂
CN1748758A (zh) 血竭凝胶制剂及其制备方法
EP0137807A1 (fr) Composition antivirale et son procede d'administration
JPH06199672A (ja) 活性成分としてクロラムフェニコール、ゲンタマイシンおよびナイスタチンを含有する、炎症性皮膚疾患の局所治療のための配合製剤
Lund et al. AN EVALUTION of Epidural Analgesia in Geriatric Surgery
RU2442565C1 (ru) Лечебная мазь
EP1291039B1 (fr) Utilisation d'un mélange de lidocaine et prilocaine, et composition pour anesthésie locale tumescente
EP1507524A1 (fr) Utilisation de diur tiques pour traiter les oed mes
CA1066620A (fr) Melange de proteines extraites du foie et methode d'utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1988903116

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP KP KR NO SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWP Wipo information: published in national office

Ref document number: 1988903116

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988903116

Country of ref document: EP